Enovis Management
Management criteria checks 3/4
Enovis' CEO is Matt Trerotola, appointed in Jul 2015, has a tenure of 9.33 years. total yearly compensation is $10.77M, comprised of 10% salary and 90% bonuses, including company stock and options. directly owns 0.32% of the company’s shares, worth $8.31M. The average tenure of the management team and the board of directors is 5.8 years and 4.3 years respectively.
Key information
Matt Trerotola
Chief executive officer
US$10.8m
Total compensation
| CEO salary percentage | 10.0% |
| CEO tenure | 9.3yrs |
| CEO ownership | 0.3% |
| Management average tenure | 5.8yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt
Sep 24
It's A Story Of Risk Vs Reward With Enovis Corporation (NYSE:ENOV)
Aug 20Enovis Languishing Despite Respectable Performance
Jul 15Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt
Jun 07Enovis: Solid Growth, But Unstable Financial Footing
May 05Enovis Corporation (NYSE:ENOV) Might Not Be As Mispriced As It Looks
Apr 22Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)
Feb 12Is Enovis (NYSE:ENOV) Using Too Much Debt?
Jan 14Investors Holding Back On Enovis Corporation (NYSE:ENOV)
Dec 18Calculating The Fair Value Of Enovis Corporation (NYSE:ENOV)
Nov 05Enovis Making Good Choices, But Not Seeing The Rewards
Sep 27Is Enovis (NYSE:ENOV) A Risky Investment?
Sep 22Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)
Aug 03Enovis Corporation: Things Are Looking Good As Guidance Is Raised
Jul 18We Think Enovis (NYSE:ENOV) Has A Fair Chunk Of Debt
Jun 20Enovis Corporation Q4 2022 Earnings Preview
Feb 22Is Enovis (NYSE:ENOV) A Risky Investment?
Feb 22Is Enovis Corporation (NYSE:ENOV) Worth US$60.5 Based On Its Intrinsic Value?
Jan 25Enovis Corporation reports Q3 earnings beat; updates FY22 guidance
Nov 02Is Enovis (NYSE:ENOV) A Risky Investment?
Oct 19Is Enovis Corporation (NYSE:ENOV) Trading At A 27% Discount?
Sep 14Enovis launches augmented reality system ARVIS for use in hip, knee surgery
Jul 19Here's Why Enovis (NYSE:ENOV) Can Manage Its Debt Responsibly
Jul 05Enovis announces CFO transition
Jun 30Enovis: Medtech Leftover Of Colfax With Some To Prove
May 23As The Colfax Chapter Ends, Both ESAB And Enovis Have Something To Prove
Apr 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 27 2024 | n/a | n/a | -US$121m |
| Jun 28 2024 | n/a | n/a | -US$107m |
| Mar 29 2024 | n/a | n/a | -US$103m |
| Dec 31 2023 | US$11m | US$1m | -US$54m |
| Sep 29 2023 | n/a | n/a | -US$112m |
| Jun 30 2023 | n/a | n/a | -US$159m |
| Mar 31 2023 | n/a | n/a | -US$23m |
| Dec 31 2022 | US$12m | US$1m | -US$39m |
| Sep 30 2022 | n/a | n/a | US$1m |
| Jul 01 2022 | n/a | n/a | US$54m |
| Apr 01 2022 | n/a | n/a | -US$109m |
| Dec 31 2021 | US$14m | US$1m | -US$103m |
| Oct 01 2021 | n/a | n/a | -US$48m |
| Jul 02 2021 | n/a | n/a | -US$18m |
| Apr 02 2021 | n/a | n/a | US$21m |
| Dec 31 2020 | US$8m | US$1m | -US$75m |
| Oct 02 2020 | n/a | n/a | US$53m |
| Jul 03 2020 | n/a | n/a | US$39m |
| Apr 03 2020 | n/a | n/a | US$42m |
| Dec 31 2019 | US$8m | US$1m | US$8m |
| Sep 27 2019 | n/a | n/a | US$10m |
| Jun 28 2019 | n/a | n/a | US$21m |
| Mar 29 2019 | n/a | n/a | US$66m |
| Dec 31 2018 | US$3m | US$1m | US$108m |
| Sep 28 2018 | n/a | n/a | -US$115m |
| Jun 29 2018 | n/a | n/a | -US$84m |
| Mar 30 2018 | n/a | n/a | -US$92m |
| Dec 31 2017 | US$3m | US$1m | US$28m |
Compensation vs Market: Matt's total compensation ($USD10.77M) is above average for companies of similar size in the US market ($USD6.60M).
Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.
CEO
Matt Trerotola (57 yo)
9.3yrs
Tenure
US$10,774,635
Compensation
Mr. Matthew L. Trerotola, also known as Matt, has been the Chief Executive Officer of Enovis Corporation (formerly known as Colfax Corporation) since July 24, 2015 and had been its President from July 2015...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 9.3yrs | US$10.77m | 0.32% $ 8.3m | |
| Senior VP & CFO | 1.8yrs | US$2.36m | 0.063% $ 1.6m | |
| Senior VP & Chief Human Resources Officer | 5.8yrs | US$2.07m | 0.040% $ 1.0m | |
| Executive Vice President of Strategy & Business Development | 11.3yrs | US$4.75m | 0.15% $ 4.0m | |
| Executive Advisor & Director | 8yrs | US$5.20m | 0.11% $ 2.9m | |
| VP, Controller & Chief Accounting Officer | 2.5yrs | no data | 0.012% $ 300.6k | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior VP & Chief Legal Officer | 5.8yrs | no data | 0.045% $ 1.2m | |
| Vice President of Corporate Communication | no data | no data | no data | |
| President of U.S. Surgical and Global Product & Enabling Technologies | less than a year | no data | no data | |
| Group President Prevention & Recovery | no data | no data | 0.035% $ 912.2k | |
| Secretary | no data | no data | no data |
5.8yrs
Average Tenure
56.5yo
Average Age
Experienced Management: ENOV's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 9.3yrs | US$10.77m | 0.32% $ 8.3m | |
| Executive Advisor & Director | 2.6yrs | US$5.20m | 0.11% $ 2.9m | |
| Lead Independent Director | 8.4yrs | US$316.46k | 0% $ 0 | |
| Independent Director | 14.2yrs | US$308.93k | 0.0044% $ 115.1k | |
| Independent Director | 2.6yrs | US$296.46k | 0.022% $ 562.9k | |
| Independent Director | 16.5yrs | US$298.93k | 0.039% $ 1.0m | |
| Independent Director | 4.8yrs | US$283.93k | 0.023% $ 603.3k | |
| Independent Director | 3.8yrs | US$283.93k | 0.015% $ 383.0k | |
| Independent Director | 2.6yrs | US$283.93k | 0.015% $ 383.0k | |
| Independent Director | 2.6yrs | US$283.93k | 0.015% $ 383.0k |
4.3yrs
Average Tenure
57yo
Average Age
Experienced Board: ENOV's board of directors are considered experienced (4.3 years average tenure).